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Abstract
Introduction: Lipid-lowering therapy should achieve target levels. We assessed
the change of the achievement of targets and the mean low-density lipoprotein
cholesterol (LDL-C) levels in high-risk Hungarian patients. 
Material and methods: Six studies performed with patients of general
practitioners (GPs) and specialists between 2004 and 2008 were evaluated:
9,508 patients from GPs and 2809 from specialist practices (total 12,317). 
Results: During this 4-year period the LDL-C level decreased by 0.73 mmol/l and
the LDL-C goal achievement rate increased from 14 to 32% in patients treated
by GPs. LDL-C showed a decrease of 0.48 mmol/l and the goal achievement rate
changed from 20 to 43% in patients treated by specialists. In the majority of
the patients not achieving the LDL-C goal (57% for specialists and 89% for GPs)
there was no modification in the current therapy. In addition to emphasizing
the priority of LDL-C lowering, we should also strive for residual risk reduction,
which means raising high-density lipoprotein cholesterol (HDL-C) and lowering
triglyceride levels. There was no significant improvement in HDL-C or triglyceride
levels during the examined period. 
Conclusion: More attention needs to be paid to changing treatment of patients
to achieve target levels. 
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Introduction
Cardiovascular (CV) diseases are the main cause of death in adults
although in Western Europe and the USA a slight and continuous
improvement has been observed for several decades. In Hungary this
tendency began in 1993 and during the last 15 years life expectancy at
birth has increased by 4.14 years; reduced CV mortality contributed to this
improvement by 1.85 years [1]. 
Life expectancy increased by 6 years between 1970 and 2000 in the
USA, and 3.9 years of that increase can be attributed to reductions in CV
disease mortality. Three quarters of the decline in coronary heart disease
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(CHD) mortality was due to secondary prevention
and other improvements in treatment, with primary
prevention accounting for only one quarter [2].
The Finnish database system made it possible to
analyse the reasons behind the 63% improvement
in CHD mortality between 1982 and 1997. Nearly one
quarter (23%) of this result is attributable to
improved therapeutic interventions (resuscitation,
fibrinolysis, percutaneous coronary intervention and
bypass surgery). The majority of the improvement
(53-72%) was achieved through the reduction of risk
factors (cholesterol, hypertension, smoking), and the
treatment of elevated lipid levels was especially
effective (37%) [3]. Similarly, results from other
countries have shown the close relation between risk
factor changes and occurrence of CV diseases [4, 5].
Reduction of total cholesterol and low-density
lipoprotein cholesterol (LDL-C) level significantly
lowers the incidence of CV events, as evidenced by
primary and secondary prevention trials [6]. Statins
are the first-line medications in lipid-lowering therapy.
According to data obtained from meta-analyses, the
reduction of LDL-C levels by 1 mmol/l results in 
a 12-15% decrease in total mortality and a 19-28%
decrease in mortality related to CHD [6, 7].
Based on the results of clinical trials it can be
concluded that a greater LDL-C lowering results in
a greater reduction of CV events [8]. In the light of
these data, prevention consensus conferences in
Hungary determined different risk categories and
the associated therapeutic goals to be achieved for
more efficient medical care [9]. Subsequently,
general practitioners (GPs) and specialists were
informed via journals, at scientific congresses and
symposia in order for these guidelines to be
implemented in routine clinical practice. Currently,
statins are administered to more than 600,000
patients in Hungary (partly due to available generic
statins) [10].
We assessed how more efficiently applied lipid-
lowering therapies changed patient mean lipid
levels. 
Material and methods
Data of studies published in Hungary between
2004 and 2008 were used (CEL Program 2004 and
2005 [11], KONSZENZUS-CEL Program 2006 [12],
REALITY 2004 and 2007 studies [13-15] and MULTI
GAP 2008 [16]). These studies assessed the effect
of treatment of patients in GPs and specialist
practices. The evaluation of the high-density
lipoprotein cholesterol (HDL-C) was not a criterion
to participate in these studies. In the present survey
only patients with a history of a CV event and on
a lipid-lowering therapy for at least 1 month were
enrolled and we excluded those in whom the LDL-C
calculation was not possible (no HDL-C available or
triglyceride level > 4.5 mmol/l). 
In the series of the CEL Program [11] primary care
physicians were made aware of the current
consensus recommendations, and subsequently
the broader use of guidelines and the adoption of
an up-to-date CV therapeutic approach were
promoted. GPs willing to participate after
a preliminary survey were educated using centrally
provided information by 4 national and the county-
level coordinators. Patient eligibility criteria were
known CV disease or asymptomatic individuals with
at least 2 risk factors. In the CEL Program 2004 [11]
18,142 patients of 320 GPs participated, and data
of a subgroup of 15,404 were assessed during 
a 3-month follow-up period, and 6,455 were
enrolled in the present survey [10]. In CEL 2005 [12]
12,101 patients of 200 GPs and in KONSZENZUS-CEL
Program 2006 [12] 11,826 patients of 68 GPs were
enrolled; 993 and 505 could participate in the
present study. Treatment strategies of the last 10-
15 patients with CV events treated by 79 internists,
48 diabetologists, 61 cardiologists, 42 neurologists
and 53 GPs were assessed retrospectively in the
MULTI-GAP study [16]. In total, the results of 4214
patients were entered anonymously into the
present analysis database: 523 from the GP group
and 1466 from the specialist group. 
The REALITY studies [13-15] were conducted in
2004 and November 2007. From the results of the
year 2004, the data of 440 patients on lipid-
lowering therapies were evaluated, 10 patients
being enrolled per physician: 300 patients were
treated by GPs and 140 by specialists; 201 and 
120 could participate in the present survey [13, 14].
In the REALITY study conducted in 2007 [15], 
4214 patients were enrolled: 784 patients were
treated by GPs, and 523 were considered in 
the present survey. From the 911 patients of 
61 cardiologists, 1175 patients of 79 internists, 
719 patients of 48 diabetologists and 625 patients
of neurologists, 1466 participated in the present
study [14]. Altogether the data of 9,508 patients
from GPs and 2,809 from specialist practices (total
12,317) were evaluated. Table I shows the
distribution and numbers according to the year of
the investigation.
The risk stratification of patients was done
according to the 3rd Hungarian Therapeutic
Consensus Conference [9]. All the patients were at
least at high risk with a history of a CV event. The
target LDL-C value was 2.5 mmol/l. We know that
some of the participants were at very high CV risk
(with a 1.8 mmol/l LDL-C target level) but because
of the lack of sufficient data their retrospective
definition was not possible. 3.0 mmol/l would be
the target value in patients at high risk but without
symptoms of atherosclerosis.
The study was conducted in accordance with the
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Conference on Harmonisation – Good Clinical
Practice). Informed consent was obtained from each
subject. 
Statistical analyses
Descriptive statistics are presented as
frequencies and percentages for categorical
variables and as the mean values ± SD for
continuous variables. Because of the skewed
distribution, TG levels are presented as median and
interquartile range and were log-transformed before
statistical testing. Categorical variables were
compared using the χ2 test. Paired Student's 
t-test was used for continuous parametric variables.
Wilcoxon signed-rank test was used for continuous
variables that were not normally distributed. All
tests were two-sided, and p values < 0.05 were
considered statistically significant. Statistical
analyses were performed with SPSS 7.5
Results
There was a significant change in mean lipid
parameters of patients treated by GPs in the past
5 years, mainly reflected by the reduction of mean
LDL-C levels. 
In the CEL Program 2004, as a result of the
therapy of patients with a prior CV event a mean
LDL-C level of 3.78 mmol/l was achieved, which is
surprisingly high, i.e. far above the desired level of
2.5 mmol/l. There was a significant improvement
in LDL-C levels during the next 4 years, with a mean
value of 3.05 mmol/l in 2008. Efficiency of the
treatment improved by 0.73 mmol/l during the
examined 5-year period (Figure 1). If this tendency
continues, the mean value will be closer to the
target of 2.5 mmol/l, but will still not reach it in the
next 3 years. 
Three studies were available addressing the
efficacy of lipid-lowering therapies in patients with
prior CV events treated by specialists. Mean LDL-C
level of treated patients was 3.34 mmol/l in 2004,
whereas it was 2.85 mmol/l in the MULTI GAP study
in 2008, a value much closer to the target of 
2.5 mmol/l. The absolute change of nearly 0.5 mmol/l
shows a significant improvement over 5 years
(Figure 1). 
The change of treatment efficacy is specially
marked if LDL-C distribution of treated patients is
studied (Figure 2). Data of CEL Program 2004 show
a Gaussian curve and despite the treatment the
proportion of patients below 2.5 mmol/l is
apparently very low. 2008 brought a left shift of the
distribution curve. Area under the curve of the
target value is about double that of 2004. The
proportion of patients with LDL-C over 3 mmol/l –
3.0 mmol/l would be the target value in high-risk
patients without symptoms [9] – at GPs remained
high; it was 72% in 2004, and despite the
considerable improvement, 51% in 2008. 1.8 mmol/l
(the target value for patients at very high risk,
which has major implications for the progression
of atherosclerosis), was achieved in 2004 in only
5% of the patients, whereas in 2008 it was achieved
in 20%.
Two-year data are available about the
distribution of LDL-C levels of patients treated by
specialists and these data show a significant
difference even within such a short period of time.
CEL 2004 CEL 2005 KONSZENZUS-CEL R EALITY 2007 MULTI GAP
REALITY 2004 Program 2006 2008
General practitioner 6455 + 201 993 505 831 523
Specialist 120 1223 1466
Table I. Size of patient populations compared across the studies
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Figure 1. Change in mean LDL cholesterol levels of
patients at high CV risk treated by GPs and
specialists over the years
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Figure 2. Distribution of LDL cholesterol levels of
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Forty-one percent of patients had an LDL-C value
below 2.5 mmol/l in 2008; 19% of them also
achieved the target value of 1.8 mmol/l. At the same
time 37% of patients at high risk cared by
specialists required further therapeutic intervention,
because even after treatment their LDL-C levels
remained above 3.0 mmol/l.
Fourteen percent of patients at high CV risk
treated by GPs achieved the guideline goal of 
2.5 mmol/l LDL-C in 2004, and this percentage was
improved to 32% by 2008. Those achieving the total
cholesterol goal of 4.5 mmol/l improved from 9%
to 24% (Figure 3). 
Patients treated by specialists achieving the 
LDL-C goal value of 2.5 mmol/l improved from 20%
to 43% over 5 years, and also achievement of the
total cholesterol goal value showed a favourable
tendency (Figure 4). 
In Hungary between 2004 and 2008 a progres  -
sively higher proportion of patients treated by GPs
and specialists achieved target LDL-C values. But
in 57% of patients treated by specialists and 89%
of them treated by GPs the insufficient treatment
was not modified in those with lipid values above
the target level in 2008 [16].
Regarding the lipid-lowering therapy, simvastatin
was the most frequently prescribed (72%) by GPs
in 2004, whereas in 2008 atorvastatin was in the
first place (46%) and 7% of the patients received
rosuvastatin. At the same time, combination
treatment also became more frequent (12%) by
2008, using the cholesterol absorption inhibitor
ezetimibe. Specialists applied more aggressive
treatment with higher doses of statin and more
combination therapies (29%).
Triglyceride levels did not change as significantly
as LDL-C levels. GP patients experienced a reduction
of 0.3 mmol/l of the average value (from 2.3 mmol/l
to 2.0 mmol/l) between 2004 and 2008. There was
no difference in the efficacy of triglyceride
treatment between GPs and specialists (specialists
also had a reduction of the mean value from 
2.3 mmol/l to 2.0 mmol/l).
An unfavourable change was observed in HDL-C
levels of the GP patients (the mean level declined
from 1.37 mmol/l to 1.30 mmol/l). At the same time
it showed an increase from 1.2 mmol/l to 1.3 mmol/l
in patients followed up by specialists. 
Discussion
Cardiovascular prevention is undergoing a substan  -
tial transformation. The importance of emergency
care is indisputable, but it is already evident that
CV morbidity and mortality can be significantly
modified by the application of prevention guidelines
[9]. The everyday prevention activity is determined
by these guidelines, of which one of the most
important fields is lipid-lowering therapy, which is
facing a qualitative change. It is important that all
patients in need receive lipid-lowering therapy but
more and more attention has to be paid to goal
achievement as this may cause an optimal
reduction of events. The change in lipid-lowering
therapy and lipid target value achievement between
2004 and 2008 in 12,317 high-risk Hungarian
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Figure 3. The improvement of LDL cholesterol and
total cholesterol goal achievement in patients at high
risk treated by GPs over the years
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Figure 4. Distribution of LDL cholesterol and total
cholesterol goal achievement in patients at high risk
treated by specialists over the years
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Figure  5.  Comparison of LDL cholesterol goal
achievement in the countries of the CEPHEUS study
and the present study
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patients was examined in a meta-analysis of four
different studies.
The 0.7 mmol/l decrease in LDL-C level in
patients treated by GPs was a result of the
improvement of therapy over the 5 years and was
associated with a significant risk reduction in these
secondary prevention patients. A meta-analysis
published in 2007 [6] based on 261,616 patients
showed that 1.0 mmol/l LDL-C reduction was
associated with a 27% reduction of CV morbidity
and a 28% reduction of mortality. Therefore, a 20%
relative risk reduction can be expected from
improvement of the lipid-lowering strategy by GPs.
It is difficult to judge the effect of this reduction on
the Hungarian morbidity and mortality measures,
but it is coincident with the favourable trend [1]. 
The improvement of results can be explained by
many factors. Besides consensus conferences held
every 2 years and emphasizing guidelines issued at
these conferences and international recom  -
mendations, regular education, publications and
also the change in therapeutic strategies
contributed to the higher proportion of goal
achievement. It has to be emphasized that even
during this relatively short period a substantial
change in the statin therapy was observed: the use
shifted from simvastatin to atorvastatin and
rosuvastatin. At the same time, combination
treatment also became more frequent by 2008: 12%
in GPs’, and 29% in specialists’ patients. Differences
in LDL-C values of these two groups are due 
to more combination therapies used and 
stronger lipid-lowering therapies that are more
readily available to specialists (i.e. in Hungarian
clinical practice only specialists can make
a recommendation to use these). A further
limitation to therapeutic efficacy might have been
patient adherence and persistence, which were not
examined in this study. 
Hermans et al. [17] have studied the LDL-C goal
achievement rate according to the European
guidelines of 2003 (Third Joint Task Force) in 
14,478 patients treated with lipid-lowering drugs in
8 countries in the Centralized Pan-European survey
on the under-treatment of hypercholesterolaemia
(CEPHEUS). In a population with a mean age of 
63.2 years with 45% women the goal was achieved
in 55.3% of the patients in 2006-2007. The rates in
the different countries are presented in Figure 5,
which also shows the target level attainment in the
present Hungarian patients treated by GPs and
specialists. The comparison should be made with
caution as the design of the 2 studies is not the
same, but it is obvious that in Hungary there is a lot
to do in this field. 
A French study performed upon the WHO
MONICA survey ascertained a 5.7% decline in the
LDL-C level between 1996 and 2007 among 35-64
year old people (p < 0.001). The reduction was
marked in the 55-64 year old group, 10.8% in men,
8.4% in women. At the same time, for triglyceride
levels a 7.8% elevation was found (p < 0.001). In the
patients receiving lipid-lowering drugs the LDL-C
decrease was 17.6% (p < 0.001) [18]. 
In the EUROASPIRE studies in Hungary a better
goal achievement rate was described (2.5 mmol/l
LDL-C attained in 40% of the patients) [19, 20].
These surveys were conducted in academic
hospitals and the study population was not
representative. We believe that our results are more
characteristic of the Hungarian real life. 
Besides the achievement of an optimal LDL-C
level [21], a new goal is the reduction of residual risk
by the elevation of low HDL-C levels and reduction
of high triglyceride levels [22]. Not very favourable
changes have been seen in this field since 2004:
only a 0.3 mmol/l reduction of the triglyceride level
accompanied by a reduction of the HDL-C level.
These results set the further course of lipid-lowering
therapy, i.e. beside efforts made to achieve the
target LDL-C values, more attention has to be paid
to increasing HDL-C levels and reducing triglyceride
levels. The changes observed in the present study
(i.e. a very slight decrease of triglyceride level and
a non-concordant change in HDL-C level) could be
explained by the fact that up to now no attention
was focussed on the residual lipid risk, and the
primary goal was LDL-C lowering. This assumption
is supported by the study of Ferrie `res et al. [18],
where beside the favourable changes in LDL-C,
a 7.8% increase of triglyceride level occurred.
In conclusion, our survey highlights a favourable
improvement in lipid-lowering therapy in the last 
5 years in Hungary, but the suboptimal rate of the
LDL-C goal attainment also has to be emphasized.
How could we further improve our treatment? 
The use of more potent statins and the
widespread application of combination therapy
could result in more common LDL-C goal
attainment. In the majority of the patients not
achieving the LDL-C goal (57% of specialists’ and
89% of GPs’ patients) there was no modification in
the current therapy. Knowing this fact, the most
important task for the near future is to pay more
attention to changing the therapy of patients
presenting lipid values over the target levels at
follow-up visits. And beside the LDL-C reduction, for
controlling the total lipid profile, more attention has
to be paid to elevated triglyceride and low HDL-C
levels too. 
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